Mefenamic Acid (250mg) + Tranexamic Acid (500mg)
Trim Plus 500mg/250mg Tablet is used in the treatment of heavy menstrual bleeding and menstrual pain.
10 tablets in 1 strip
Image shown is a representation and may slightly vary from the actual product. Every effort is made to maintain accuracy of all information displayed.
Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it.
Trim Plus 500mg/250mg Tablet is a combination of two medicines: Tranexamic Acid and Mefenamic Acid. Tranexamic Acid is an anti-fibrinolytic. It works by preventing the breakdown of blood clots to control excessive bleeding during periods. Mefenamic Acid is a non-steroidal anti-inflammatory drug (NSAID) which blocks the production of certain chemical messengers (prostaglandins) that cause pain and inflammation (redness and swelling).
Related Warnings
Taking Mefenamic acid with alcohol increases the risk of stomach bleeding.
Trim Plus 500mg/250mg Tablet may be unsafe to use during pregnancy.
Animal studies have shown adverse effects on the foetus, however, there are limited human studies. The benefits from use in pregnant women may be acceptable despite the risk. Please consult your doctor.
Trim Plus 500mg/250mg Tablet is probably safe to use during lactation. Limited human data suggests that the drug does not represent a significant risk to the baby.
Trim Plus 500mg/250mg Tablet may make you feel dizzy, drowsy or affect your vision. Do not drive until your vision is clear.
Trim Plus 500mg/250mg Tablet should be used with caution in patients with kidney disease. Dose adjustment of Trim Plus 500mg/250mg Tablet may be needed. Please consult your doctor.
Use of Trim Plus 500mg/250mg Tablet is not recommended in patients with severe kidney disease.
Trim Plus 500mg/250mg Tablet is probably safe to use in patients with liver disease. Limited data available suggests that dose adjustment of Trim Plus 500mg/250mg Tablet may not be needed in these patients. Please consult your doctor.
